Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesEpidemiology and Outcomes
You have accessRestricted Access

Quantification of HDL Proteins, Cardiac Events, and Mortality in Patients with Type 2 Diabetes on Hemodialysis

Chantal Kopecky, Bernd Genser, Christiane Drechsler, Vera Krane, Christopher C. Kaltenecker, Markus Hengstschläger, Winfried März, Christoph Wanner, Marcus D. Säemann and Thomas Weichhart
CJASN February 2015, 10 (2) 224-231; DOI: https://doi.org/10.2215/CJN.06560714
Chantal Kopecky
*Department of Internal Medicine III, Division of Nephrology and Dialysis and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernd Genser
†BGStats Consulting, Vienna, Austria;
‡Mannheim Institute of Public Health, Social and Preventive Medicine, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany;
§Institute of Public Health, Federal University of Bahia, Salvador, Brazil;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Drechsler
║Department of Medicine, Division of Nephrology, University Hospital, Würzburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vera Krane
║Department of Medicine, Division of Nephrology, University Hospital, Würzburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher C. Kaltenecker
*Department of Internal Medicine III, Division of Nephrology and Dialysis and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Hengstschläger
¶Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Winfried März
**Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria;
††Medical Clinic V (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), Mannheim Medical Faculty, Heidelberg University, Mannheim, Germany; and
‡‡Synlab Academy, Synlab Laboratory Services GmbH, Mannheim, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Wanner
║Department of Medicine, Division of Nephrology, University Hospital, Würzburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus D. Säemann
*Department of Internal Medicine III, Division of Nephrology and Dialysis and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Weichhart
¶Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Background and objectives Impairment of HDL function has been associated with cardiovascular events in patients with kidney failure. The protein composition of HDLs is altered in these patients, presumably compromising the cardioprotective effects of HDLs. This post hoc study assessed the relation of distinct HDL-bound proteins with cardiovascular outcomes in a dialysis population.

Design, setting, participants, & measurements The concentrations of HDL-associated serum amyloid A (SAA) and surfactant protein B (SP-B) were measured in 1152 patients with type 2 diabetes mellitus on hemodialysis participating in The German Diabetes Dialysis Study who were randomly assigned to double-blind treatment of 20 mg atorvastatin daily or matching placebo. The association of SAA(HDL) and SP-B(HDL) with cardiovascular outcomes was assessed in multivariate regression models adjusted for known clinical risk factors.

Results High concentrations of SAA(HDL) were significantly and positively associated with the risk of cardiac events (hazard ratio per 1 SD higher, 1.09; 95% confidence interval, 1.01 to 1.19). High concentrations of SP-B(HDL) were significantly associated with all-cause mortality (hazard ratio per 1 SD higher, 1.10; 95% confidence interval, 1.02 to 1.19). Adjustment for HDL cholesterol did not affect these associations.

Conclusions In patients with diabetes on hemodialysis, SAA(HDL) and SP-B(HDL) were related to cardiac events and all-cause mortality, respectively, and they were independent of HDL cholesterol. These findings indicate that a remodeling of the HDL proteome was associated with a higher risk for cardiovascular events and mortality in patients with ESRD.

  • dialysis
  • cardiovascular disease
  • lipids

Introduction

Numerous epidemiologic, clinical, and experimental studies showed an association between low HDLs and increased cardiovascular risk (1). The cardioprotective properties of HDLs are thought to include the efflux of cholesterol from macrophages, enhancement of endothelial function, antioxidative and anti-inflammatory activities (2–5). Emerging evidence suggests that the mere cholesterol content of HDL (HDL-C) is insufficient to estimate the cardioprotective functions of HDLs. Pharmacologic increase of HDL-C was not uniformly associated with a reduction of cardiovascular risk in several high-risk populations (6–9). Moreover, the ability of HDLs to promote cholesterol removal from macrophages was shown to be inversely associated with cardiovascular risk independent of HDL-C (10). These and other findings raised the hypotheses that merely increasing the cholesterol content of HDLs is not necessarily beneficial and does not reflect HDL functionality (11–16).

Patients with CKD harbor an exceptionally high cardiovascular risk (17,18). Despite a direct association of low HDL-C with reduced kidney function (19,20), the relation of HDL-C with cardiovascular events and mortality in CKD and ESRD is inconsistent. For example, a study found that HDL-C was predictive of incident myocardial infarction in Japanese patients on hemodialysis without history of cardiovascular disease (CVD) (21), whereas no association of HDL-C with all-cause or cardiovascular mortality was found in European patients with CKD (22,23). Importantly, a recent post hoc analysis of the cohort from The German Diabetes Dialysis Study (the 4D Study) has shown that HDL-C is not predictive of all-cause mortality or cardiovascular events in this population (23). Additionally, HDL functions are severely impaired in patients with ESRD and importantly, directly related to structural alterations of HDLs (24–27). Together, this evidence indicates that the effect of HDL-C is modulated by renal function and that the atheroprotective HDL particles may be rendered dysfunctional in the setting of CKD.

HDLs are a family of heterogeneous particles that vary 4-fold in cholesterol content (28,29) and carry a protein cargo of >50 different proteins (30,31). The protein composition of HDLs emerges as important determinant when investigating the association between HDL function or concentration and CVD (30,32). For example, individual proteins were found enriched or depleted in HDLs from patients with diseases that bear major cardiovascular risks, such as ESRD, coronary artery disease, or rheumatoid arthritis (25,26,31,33–35). Most consistently, serum amyloid A (SAA) is enriched in HDLs isolated from patients with these diseases compared with the HDLs from healthy individuals. Moreover, SAA accumulation in HDLs contributes to decreased protective functions of HDLs, including reduced anti-inflammatory properties (25,33). In addition, surfactant protein B (SP-B) was found highly enriched in HDLs from individuals with ESRD and coronary artery disease (25,32). These findings suggest that remodeling of the HDL proteome contributes to the cardiovascular risk in these diseases.

We hypothesized that the amount of SAA and SP-B bound to HDLs, which we termed SAA(HDL) and SP-B(HDL), respectively, from patients with kidney failure might affect clinical events or mortality. Therefore, we performed a post hoc analysis of the 4D Study by measurement of SAA(HDL) and SP-B(HDL) concentrations in patients with type 2 diabetes on hemodialysis and assessed their associations with defined cardiovascular end points and mortality.

Materials and Methods

Design, Setting, and Participants

Design and methods of the 4D Study have been reported previously (36–38). The 4D Study was a double-blinded, randomized, multicenter trial including 1255 patients with type 2 diabetes mellitus who were 18–80 years of age and had a previous duration of hemodialysis of <2 years. Between March of 1998 and October of 2002, patients were recruited and randomly assigned to receive either treatment with 20 mg atorvastatin one time daily (n=619) or placebo (n=636). Participants were followed up at 4 weeks and every 6 months after randomization. At each follow-up visit, a blood sample was taken, and information about any suspected end point or serious adverse event was recorded.

Laboratory Procedures

We determined the concentrations of SAA(HDL) and SP-B(HDL) at baseline in available serum samples from the 4D Study with a newly developed ELISA. Briefly, apolipoprotein B–depleted serum was added to human HDL antibody–coated ELISA plates, and SAA(HDL) or SP-B(HDL) was detected by respective primary antibodies. The intra-assay values for variability for SAA(HDL) and SP-B(HDL) expressed by the correlation of variance were 10.9% and 21.6%, respectively. The correlation of variance values for the interassay variability were 15.9% for SAA(HDL) and 29.8% for SP-B(HDL). A detailed description and validation of our assay can be found in the Supplemental Material.

End Points

For the post hoc analysis presented here, we evaluated the following end points: (1) combined primary end point (composite of cardiac death, nonfatal myocardial infarction, or stroke), (2) cardiac death, (2a) sudden cardiac death, (3) nonfatal myocardial infarction, (4) fatal stroke, (5) nonfatal stroke, (6) all cardiac events combined (cardiac death and nonfatal myocardial infarction), (7) all cerebrovascular events combined, (8) stroke (fatal and nonfatal combined), (9) all-cause mortality, and (10) non-CVD mortality.

Statistical Analyses

For each marker investigated (i.e., SAA[HDL] and SP-B [HDL]), we examined characteristics of subgroups defined by quartiles of serum concentrations at baseline by calculating descriptive statistics (means and SDs for continuous variables and frequency tables for categorical variables). We compared the distribution of important cardiovascular parameters across quartiles by using ANOVA (for continuous variables) or chi-squared tests (for categorical variables). We used time-to-event analysis (extended Cox regression model allowing for multiple events) aimed to (1) evaluate the association of baseline SAA(HDL) and SP-B(HDL) concentrations on end point occurrence and (2) investigate the effect of baseline marker concentrations on the efficacy of atorvastatin intervention. First, for both markers SAA(HDL) and SP-B(HDL), we conducted a pooled analysis in both randomization groups including a dummy variable for randomization group and an interaction term. Second, because we found no evidence for interaction, we fitted a model without the interaction term. We used two different model parameterizations: one model included the marker quartile as a categorical variable, and one model included the marker quartile as a continuous variable. In the continuous model, the marker values were scaled in units of the SD of the population. Additionally, to further explore effect modification, we fitted efficacy models calculating hazard ratios (HRs) for atorvastatin versus placebo stratified by marker quartiles. All models were adjusted for all significant predictor variables selected for each end point separately by using a stepwise selection procedure (forward: P=0.05; backward: P=0.10) from a set of significant covariates (39). We conducted all statistical analyses using the statistical software package STATA (StataCorp 2011, Stata Statistical Software: Release 12; StataCorp LP, College Station, TX).

Results

Baseline Characteristics of the Study Population According to SAA(HDL) and SP-B(HDL) Quartiles

Characteristics of patient subgroups were determined by defined quartiles of HDL protein levels in serum at baseline. Characteristics of the study patients according to quartiles of SAA(HDL) are shown in Table 1. The mean values of SAA(HDL)±SDs in the quartiles were 1.82 (±0.65), 4.01 (±0.85), 8.35 (±1.82), and 20.29 (±6.00). Remarkably, patients in the fourth quartile showed a 10-fold higher SAA concentration compared with patients in the first quartile. Patients in the highest SAA(HDL) quartile had a higher prevalence of arrhythmia and congestive heart failure and increased C-reactive protein (CRP) levels. In contrast, total cholesterol and triglycerides were lower in higher SAA(HDL) quartiles. There were no differences in the distribution of body mass index, sex, or HDL-C across quartiles of SAA(HDL).

View this table:
  • View inline
  • View popup
Table 1.

Baseline characteristics of the patients according to quartiles of serum amyloid A (HDL)

Characteristics of the patients according to quartiles of baseline SP-B(HDL) are presented in Table 2. The mean values of SP-B(HDL)±SDs in the quartiles were 1.66 (±1.36), 4.92 (±0.91), 9.19 (±1.75), and 22.98 (±10.11). Similar to SAA, SP-B(HDL) was >10-fold higher in the fourth quartile compared with the first quartile. Individuals in higher SP-B(HDL) quartiles had an increased prevalence of congestive heart failure and lower total cholesterol and triglycerides. Patients in higher quartiles of SAA(HDL) and SP-B(HDL) had higher SP-B(HDL) and SAA(HDL), respectively (Tables 1 and 2), which were corroborated by a positive bivariate Spearman correlation coefficient (r=0.23, P<0.001).

View this table:
  • View inline
  • View popup
Table 2.

Baseline characteristics of the patients according to quartiles of surfactant protein B (HDL)

SAA(HDL) and Cardiac Events

In an adjusted multivariate Cox regression analysis examining potential associations of SAA(HDL) with the predefined study end points (described in Materials and Methods), the concentrations of SAA(HDL) at baseline were significantly associated with the end point of all cardiac events combined (HR per 1 SD higher in SAA[HDL] levels, 1.09; 95% confidence interval, 1.01 to 1.19; P=0.04) but not with the other end points (Table 3, Supplemental Table 1). The HRs for all cardiac events combined increased in parallel with the quartiles of SAA(HDL), and in about one half of the patients in the fourth quartile, cardiac events were observed (Figure 1, Table 3). Additional adjustment for HDL-C, apolipoprotein A-I, or CRP did not affect the association between SAA(HDL) and cardiac events (Supplemental Figure 9, Supplemental Table 1). Additional adjustment for SP-B(HDL) slightly decreased the association between SAA(HDL) and cardiac events indicated by the decreased P values (Supplemental Table 1). We found a potential effect modification of SAA(HDL) according to atorvastatin treatment on cardiac events described in detail in the Supplemental Material (Supplemental Material, Supplemental Figure 11), although the overall effect was not significant (P=0.27). For all other end points investigated, we did not observe any significant interaction.

View this table:
  • View inline
  • View popup
Table 3.

End points according to quartiles of serum amyloid A (HDL)

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Hazard ratios for cardiac events according to SAA(HDL) quartiles. The dots and horizontal lines indicate HR points with 95% CI, respectively. The analysis was adjusted for following predictor variables: age, gender, phosphate, use of calcium antagonists, history of coronary artery disease, arrythmia, congestive heart failure, peripheral vascular disease. The squares and horizontal lines indicate HR points with 95% CI, respectively, adjusted for predictor variables and HDL-C.

SP-B(HDL) and All-Cause Mortality

Adjusted multivariate Cox regression analysis revealed that SP-B(HDL) was significantly associated with all-cause mortality and the single components death from cardiac causes, sudden cardiac death, and non-CVD death (Figure 2, Table 4). Notably, high SP-B(HDL) concentrations were associated with all-cause mortality (HR per 1 SD higher in SP-B [HDL] levels, 1.10; 95% confidence interval, 1.02 to 1.19; P=0.01), and about one half of the patients in the third quartile as well as approximately two thirds of the patients in the fourth quartile died (Table 4, Supplemental Table 2). This association remained significant after additional adjustment for HDL-C and SAA(HDL) (Supplemental Figure 10, Supplemental Table 2). Moreover, additional adjustment for apolipoprotein A-I or CRP did not alter the association between SP-B(HDL) and all-cause mortality (Supplemental Table 2). We did not observe any significant effect modification of atorvastatin treatment by SP-B(HDL) on any of the defined end points.

View this table:
  • View inline
  • View popup
Table 4.

End points according to quartiles of surfactant protein B (HDL)

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Hazard ratios for all-cause mortality according to SP-B(HDL) quartiles. The dots and horizontal lines indicate HR points with 95% CI, respectively. The analysis was adjusted for following predictor variables: age, gender, body mass index, total cholesterol, albumin, hemoglobin, glycated hemoglobin, phosphate, leukocytes, serum creatinine, diastolic blood pressure, duration of dialysis, duration of diabtets, use of statins, use of calcium antagonists, use of angiotension-converting enzyme inhibitors, history of coronary artery disease, ischemia, arrythmia, congestive heart failure, peripheral vascular disease. The squares and horizontal lines indicate HR points with 95% CI, respectively, adjusted for predictor variables and HDL-C.

Discussion

In this post hoc analysis of the 4D Study, we found that the HDL-associated proteins SAA and SP-B were independently associated with cardiac events and overall mortality. The associations were robust against adjustment for potential confounding variables and HDL-C. This is the first study that evaluated and found an association of distinct disease-specific proteins directly on HDL particles with cardiovascular events and all-cause mortality. Moreover, these data suggest that the increased incorporation of SAA and SP-B into HDL particles might contribute to the high risk of cardiovascular events and mortality in these patients.

Patients with ESRD requiring dialysis are among the highest risk groups for CVD and mortality (17,18). Despite reduced serum HDL-C concentrations in ESRD, most studies in the Western population did not show a clear association of HDL-C with survival or cardiac events (40–42). In contrast, HDL-C was associated with a lower risk for myocardial infarction in the Japanese population (21). The association between higher HDL-C and reduced mortality risk and coronary artery disease severity is already abrogated in patients with only mildly reduced kidney function (22). This indicates that the HDL particles not only lose their atheroprotective properties in the setting of CKD but, also, are converted into deleterious molecules. In line, accumulating data suggests that HDLs are remodeled in patients with ESRD, acquire new proteins, such as SAA or SP-B, and thus, may become dysfunctional (25–27,33). A similar conversion of HDLs to presumably dysfunctional HDLs is observed in coronary artery disease and rheumatoid arthritis (31,34). The increased risk of cardiovascular events in ESRD results from pathophysiologic processes specific to CKD, making the prevention of CVD by interventions targeting traditional risk factors difficult (17). Individuals with diabetes constitute one of the largest groups of patients on dialysis and are at higher risk of cardiovascular events and mortality compared with the nondiabetic ESRD population, highlighting the importance of elucidating novel risk factors and the underlying pathophysiologic pathways (43,44).

The enrichment of distinct proteins in HDLs in various diseases states evolves as an important determinant for associations between HDL function and cardiovascular risk (16,30,45). Our improved understanding of the composition of HDLs can enable pharmacologic attempts in manipulating HDL composition and function to reduce cardiovascular risk. Moreover, quantification of specific HDL proteins as markers of impaired cardioprotective quality might be used to establish novel diagnostic biomarkers and assess the effectiveness of current and new therapeutic interventions (45). This concept is supported by our findings indicating that dysfunctional HDLs, measured by the incorporation of SAA and SP-B, occur in human chronic inflammatory syndromes and are associated with clinical events and mortality. Nevertheless, our results do not prove causality; remodeling of HDLs either has a direct pathophysiologic role or is secondary to other processes that contribute to disease etiology.

SAA is an apolipoprotein found predominantly in HDLs (46). SAA is a major acute-phase protein that is secreted in large amounts by the liver during infections or inflammatory processes. Increased incorporation of SAA into HDLs was documented in a number of chronic inflammatory diseases, most prominently in patients on dialysis, indicating that the presence of SAA in HDLs is a marker of ongoing inflammation (25,26,31,33,34). This hypothesis is supported by the correlation between SAA(HDL) and CRP in our study. However, only about 10% of the variance of CRP concentrations could be explained by SAA(HDL) quartiles (R2=0.10), and adjustment for CRP did not affect the association between SAA(HDL) and cardiac events.

SP-B has been detected in the HDLs of patients with ESRD and coronary artery disease (25,32). Moreover, SP-B accumulates in blood of individuals with acute respiratory distress syndrome and chronic heart failure (47,48). In addition, serum SP-B was associated with abdominal aortic plaques in current smokers (48). Pulmonary edema and pleural effusion are common in chronic heart failure and ESRD and may result in damage to the alveolar-capillary membrane. Consequently, SP-B is released into the circulation and may become incorporated into HDLs. SP-B(HDL) was not associated with CRP in our study, and adjustment for SAA(HDL) did not alleviate the association between SP-B(HDL) and mortality, suggesting that the pathogenetic mechanism that promotes incorporation of SP-B into HDLs is independent of inflammation.

There is increasing evidence that HDL-C does not affect cardiovascular events in different patient populations, because the amount of cholesterol within the HDL fraction does not necessarily correlate with the biologic functions of HDLs (6–8,11–13,49). Consequently, there is a strong need to develop new metrics for HDL functionality that are technically feasible and provide clinically applicable and relevant information in large and diverse populations. In such an effort, it was shown that the ability of HDLs to promote cholesterol efflux from macrophages correlates better and inversely with cardiovascular risk (10). However, this method of quantifying HDL function is technically challenging and therefore, unlikely to be widely applicable to clinical studies. In addition, HDL size and particle number assessed by nuclear magnetic resonance spectroscopy showed to be better predictors of cardiovascular risk than serum concentrations of HDL-C (50). Another approach that has been recently proposed to assess HDL quality is to monitor the protein cargo of HDLs (49). The findings of our study support this concept and provide evidence that quantification of individual HDL-associated proteins by a simple ELISA-based approach is useful to identify modified HDLs that are potentially relevant for clinical end points. Our results support the hypotheses that dysfunctional HDLs translate into clinical events and that quantification of specific HDL proteins may be used as surrogates for HDL functions.

To evaluate the full potential of SAA(HDL) and SP-B(HDL) for adverse clinical events in renal failure as well as other high-risk populations, additional studies are necessary to link HDL-associated proteins with cardiovascular risk association. Moreover, these markers might prove useful in earlier stages of CKD for assessing the risk of disease progression. Taking into account that HDL-C is associated with renal function (19,20,22), combined assessment of HDL proteins together with HDL-C could help to monitor disease progression and risk of cardiovascular outcome.

One limitation of our study is its post hoc design, and the results should be interpreted as explorative. For this reason, our data should be viewed as hypothesis-generating and thus, require additional evaluation in further studies.

In conclusion, our study provides evidence that SAA and SP-B measured directly on HDLs from patients with type 2 diabetes mellitus on hemodialysis are associated with cardiac events and mortality, respectively, independent of HDL-C. These findings suggest that remodeling of the HDL proteome contributes to the increased risk of cardiovascular events and mortality in patients with kidney disease.

Disclosures

None.

Acknowledgments

This study was supported by Else Kröner Fresenius-Stiftung Grant 010_A86 (to M.D.S. and T.W.).

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.06560714/-/DCSupplemental.

  • Received July 3, 2014.
  • Accepted October 6, 2014.
  • Copyright © 2015 by the American Society of Nephrology

References

  1. ↵
    1. Gordon DJ,
    2. Probstfield JL,
    3. Garrison RJ,
    4. Neaton JD,
    5. Castelli WP,
    6. Knoke JD,
    7. Jacobs DR Jr..,
    8. Bangdiwala S,
    9. Tyroler HA
    : High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8–15, 1989pmid:2642759
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Rye KA,
    2. Barter PJ
    : Cardioprotective functions of HDLs. J Lipid Res 55: 168–179, 2014pmid:23812558
    OpenUrlAbstract/FREE Full Text
    1. Navab M,
    2. Reddy ST,
    3. Van Lenten BJ,
    4. Fogelman AM
    : HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8: 222–232, 2011pmid:21304474
    OpenUrlCrossRefPubMed
    1. Säemann MD,
    2. Poglitsch M,
    3. Kopecky C,
    4. Haidinger M,
    5. Hörl WH,
    6. Weichhart T
    : The versatility of HDL: A crucial anti-inflammatory regulator. Eur J Clin Invest 40: 1131–1143, 2010pmid:20695882
    OpenUrlCrossRefPubMed
  3. ↵
    1. Rosenson RS,
    2. Brewer HB Jr..,
    3. Davidson WS,
    4. Fayad ZA,
    5. Fuster V,
    6. Goldstein J,
    7. Hellerstein M,
    8. Jiang XC,
    9. Phillips MC,
    10. Rader DJ,
    11. Remaley AT,
    12. Rothblat GH,
    13. Tall AR,
    14. Yvan-Charvet L
    : Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 125: 1905–1919, 2012pmid:22508840
    OpenUrlFREE Full Text
  4. ↵
    1. Schaefer EJ
    : Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: Why have they failed in lowering coronary heart disease risk? Curr Opin Lipidol 24: 259–264, 2013pmid:23652567
    OpenUrlCrossRefPubMed
    1. Barter PJ,
    2. Caulfield M,
    3. Eriksson M,
    4. Grundy SM,
    5. Kastelein JJ,
    6. Komajda M,
    7. Lopez-Sendon J,
    8. Mosca L,
    9. Tardif JC,
    10. Waters DD,
    11. Shear CL,
    12. Revkin JH,
    13. Buhr KA,
    14. Fisher MR,
    15. Tall AR,
    16. Brewer B,
    17. ILLUMINATE Investigators
    : Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109–2122, 2007pmid:17984165
    OpenUrlCrossRefPubMed
  5. ↵
    1. Schwartz GG,
    2. Olsson AG,
    3. Barter PJ
    : Dalcetrapib in patients with an acute coronary syndrome. N Engl J Med 368: 869–870, 2013pmid:23445098
    OpenUrlCrossRefPubMed
  6. ↵
    1. Mahdy Ali K,
    2. Wonnerth A,
    3. Huber K,
    4. Wojta J
    : Cardiovascular disease risk reduction by raising HDL cholesterol—current therapies and future opportunities. Br J Pharmacol 167: 1177–1194, 2012pmid:22725625
    OpenUrlCrossRefPubMed
  7. ↵
    1. Khera AV,
    2. Cuchel M,
    3. de la Llera-Moya M,
    4. Rodrigues A,
    5. Burke MF,
    6. Jafri K,
    7. French BC,
    8. Phillips JA,
    9. Mucksavage ML,
    10. Wilensky RL,
    11. Mohler ER,
    12. Rothblat GH,
    13. Rader DJ
    : Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364: 127–135, 2011pmid:21226578
    OpenUrlCrossRefPubMed
  8. ↵
    1. Briel M,
    2. Ferreira-Gonzalez I,
    3. You JJ,
    4. Karanicolas PJ,
    5. Akl EA,
    6. Wu P,
    7. Blechacz B,
    8. Bassler D,
    9. Wei X,
    10. Sharman A,
    11. Whitt I,
    12. Alves da Silva S,
    13. Khalid Z,
    14. Nordmann AJ,
    15. Zhou Q,
    16. Walter SD,
    17. Vale N,
    18. Bhatnagar N,
    19. O’Regan C,
    20. Mills EJ,
    21. Bucher HC,
    22. Montori VM,
    23. Guyatt GH
    : Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis. BMJ 338: b92, 2009pmid:19221140
    OpenUrlAbstract/FREE Full Text
    1. Voight BF,
    2. Peloso GM,
    3. Orho-Melander M,
    4. Frikke-Schmidt R,
    5. Barbalic M,
    6. Jensen MK,
    7. Hindy G,
    8. Hólm H,
    9. Ding EL,
    10. Johnson T,
    11. Schunkert H,
    12. Samani NJ,
    13. Clarke R,
    14. Hopewell JC,
    15. Thompson JF,
    16. Li M,
    17. Thorleifsson G,
    18. Newton-Cheh C,
    19. Musunuru K,
    20. Pirruccello JP,
    21. Saleheen D,
    22. Chen L,
    23. Stewart A,
    24. Schillert A,
    25. Thorsteinsdottir U,
    26. Thorgeirsson G,
    27. Anand S,
    28. Engert JC,
    29. Morgan T,
    30. Spertus J,
    31. Stoll M,
    32. Berger K,
    33. Martinelli N,
    34. Girelli D,
    35. McKeown PP,
    36. Patterson CC,
    37. Epstein SE,
    38. Devaney J,
    39. Burnett MS,
    40. Mooser V,
    41. Ripatti S,
    42. Surakka I,
    43. Nieminen MS,
    44. Sinisalo J,
    45. Lokki ML,
    46. Perola M,
    47. Havulinna A,
    48. de Faire U,
    49. Gigante B,
    50. Ingelsson E,
    51. Zeller T,
    52. Wild P,
    53. de Bakker PI,
    54. Klungel OH,
    55. Maitland-van der Zee AH,
    56. Peters BJ,
    57. de Boer A,
    58. Grobbee DE,
    59. Kamphuisen PW,
    60. Deneer VH,
    61. Elbers CC,
    62. Onland-Moret NC,
    63. Hofker MH,
    64. Wijmenga C,
    65. Verschuren WM,
    66. Boer JM,
    67. van der Schouw YT,
    68. Rasheed A,
    69. Frossard P,
    70. Demissie S,
    71. Willer C,
    72. Do R,
    73. Ordovas JM,
    74. Abecasis GR,
    75. Boehnke M,
    76. Mohlke KL,
    77. Daly MJ,
    78. Guiducci C,
    79. Burtt NP,
    80. Surti A,
    81. Gonzalez E,
    82. Purcell S,
    83. Gabriel S,
    84. Marrugat J,
    85. Peden J,
    86. Erdmann J,
    87. Diemert P,
    88. Willenborg C,
    89. König IR,
    90. Fischer M,
    91. Hengstenberg C,
    92. Ziegler A,
    93. Buysschaert I,
    94. Lambrechts D,
    95. Van de Werf F,
    96. Fox KA,
    97. El Mokhtari NE,
    98. Rubin D,
    99. Schrezenmeir J,
    100. Schreiber S,
    101. Schäfer A,
    102. Danesh J,
    103. Blankenberg S,
    104. Roberts R,
    105. McPherson R,
    106. Watkins H,
    107. Hall AS,
    108. Overvad K,
    109. Rimm E,
    110. Boerwinkle E,
    111. Tybjaerg-Hansen A,
    112. Cupples LA,
    113. Reilly MP,
    114. Melander O,
    115. Mannucci PM,
    116. Ardissino D,
    117. Siscovick D,
    118. Elosua R,
    119. Stefansson K,
    120. O’Donnell CJ,
    121. Salomaa V,
    122. Rader DJ,
    123. Peltonen L,
    124. Schwartz SM,
    125. Altshuler D,
    126. Kathiresan S
    : Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 380: 572–580, 2012pmid:22607825
    OpenUrlCrossRefPubMed
  9. ↵
    1. van Capelleveen JC,
    2. Bochem AE,
    3. Motazacker MM,
    4. Hovingh GK,
    5. Kastelein JJ
    : Genetics of HDL-C: A causal link to atherosclerosis? Curr Atheroscler Rep 15: 326, 2013pmid:23591671
    OpenUrlCrossRefPubMed
    1. Ansell BJ,
    2. Navab M,
    3. Hama S,
    4. Kamranpour N,
    5. Fonarow G,
    6. Hough G,
    7. Rahmani S,
    8. Mottahedeh R,
    9. Dave R,
    10. Reddy ST,
    11. Fogelman AM
    : Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108: 2751–2756, 2003pmid:14638544
    OpenUrlAbstract/FREE Full Text
    1. Ray K,
    2. Wainwright NW,
    3. Visser L,
    4. Witteman J,
    5. Breteler M,
    6. Ambegaonkar B,
    7. Hofman A,
    8. Stricker B,
    9. Wareham N,
    10. Khaw KT,
    11. Sandhu M
    : Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy. Heart 98: 780–785, 2012pmid:22447463
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Toth PP,
    2. Barter PJ,
    3. Rosenson RS,
    4. Boden WE,
    5. Chapman MJ,
    6. Cuchel M,
    7. D’Agostino RB Sr..,
    8. Davidson MH,
    9. Davidson WS,
    10. Heinecke JW,
    11. Karas RH,
    12. Kontush A,
    13. Krauss RM,
    14. Miller M,
    15. Rader DJ
    : High-density lipoproteins: A consensus statement from the National Lipid Association. J Clin Lipidol 7: 484–525, 2013pmid:24079290
    OpenUrlCrossRefPubMed
  11. ↵
    1. Gansevoort RT,
    2. Correa-Rotter R,
    3. Hemmelgarn BR,
    4. Jafar TH,
    5. Heerspink HJ,
    6. Mann JF,
    7. Matsushita K,
    8. Wen CP
    : Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 382: 339–352, 2013pmid:23727170
    OpenUrlCrossRefPubMed
  12. ↵
    1. Vaziri ND,
    2. Navab M,
    3. Fogelman AM
    : HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 6: 287–296, 2010pmid:20308998
    OpenUrlCrossRefPubMed
  13. ↵
    1. Wang F,
    2. Zheng J,
    3. Ye P,
    4. Luo L,
    5. Bai Y,
    6. Xu R,
    7. Sheng L,
    8. Xiao T,
    9. Wu H
    : Association of high-density lipoprotein cholesterol with the estimated glomerular filtration rate in a community-based population. PLoS ONE 8: e79738, 2013pmid:24223189
    OpenUrlCrossRefPubMed
  14. ↵
    1. Baragetti A,
    2. Norata GD,
    3. Sarcina C,
    4. Rastelli F,
    5. Grigore L,
    6. Garlaschelli K,
    7. Uboldi P,
    8. Baragetti I,
    9. Pozzi C,
    10. Catapano AL
    : High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med 274: 252–262, 2013pmid:23607805
    OpenUrlCrossRefPubMed
  15. ↵
    1. Shoji T,
    2. Masakane I,
    3. Watanabe Y,
    4. Iseki K,
    5. Tsubakihara Y,
    6. Committee of Renal Data Registry, Japanese Society for Dialysis Therapy
    : Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 6: 1112–1120, 2011pmid:21511840
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Zewinger S,
    2. Speer T,
    3. Kleber ME,
    4. Scharnagl H,
    5. Woitas R,
    6. Lepper PM,
    7. Pfahler K,
    8. Seiler S,
    9. Heine GH,
    10. März W,
    11. Silbernagel G,
    12. Fliser D
    : HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 25: 1073–1082, 2014pmid:24610925
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Silbernagel G,
    2. Genser B,
    3. Drechsler C,
    4. Scharnagl H,
    5. Grammer TB,
    6. Stojakovic T,
    7. Krane V,
    8. Ritz E,
    9. Wanner C,
    10. März W
    : HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients [published online ahead of print July 10, 2014]. J Am Soc Nephrol doi:ASN.2013080816pmid:25012163
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Kalantar-Zadeh K,
    2. Kopple JD,
    3. Kamranpour N,
    4. Fogelman AM,
    5. Navab M
    : HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 72: 1149–1156, 2007pmid:17728705
    OpenUrlCrossRefPubMed
  19. ↵
    1. Weichhart T,
    2. Kopecky C,
    3. Kubicek M,
    4. Haidinger M,
    5. Döller D,
    6. Katholnig K,
    7. Suarna C,
    8. Eller P,
    9. Tölle M,
    10. Gerner C,
    11. Zlabinger GJ,
    12. van der Giet M,
    13. Hörl WH,
    14. Stocker R,
    15. Säemann MD
    : Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 23: 934–947, 2012pmid:22282592
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Holzer M,
    2. Birner-Gruenberger R,
    3. Stojakovic T,
    4. El-Gamal D,
    5. Binder V,
    6. Wadsack C,
    7. Heinemann A,
    8. Marsche G
    : Uremia alters HDL composition and function. J Am Soc Nephrol 22: 1631–1641, 2011pmid:21804091
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Yamamoto S,
    2. Yancey PG,
    3. Ikizler TA,
    4. Jerome WG,
    5. Kaseda R,
    6. Cox B,
    7. Bian A,
    8. Shintani A,
    9. Fogo AB,
    10. Linton MF,
    11. Fazio S,
    12. Kon V
    : Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 60: 2372–2379, 2012pmid:23141484
    OpenUrlCrossRefPubMed
  22. ↵
    1. Rothblat GH,
    2. Phillips MC
    : High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 21: 229–238, 2010pmid:20480549
    OpenUrlCrossRefPubMed
  23. ↵
    1. Huang R,
    2. Silva RA,
    3. Jerome WG,
    4. Kontush A,
    5. Chapman MJ,
    6. Curtiss LK,
    7. Hodges TJ,
    8. Davidson WS
    : Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 18: 416–422, 2011pmid:21399642
    OpenUrlCrossRefPubMed
  24. ↵
    1. Gordon S,
    2. Durairaj A,
    3. Lu JL,
    4. Davidson WS
    : High-density lipoprotein proteomics: Identifying new drug targets and biomarkers by understanding functionality. Curr Cardiovasc Risk Rep 4: 1–8, 2010pmid:20625533
    OpenUrlCrossRefPubMed
  25. ↵
    1. Vaisar T,
    2. Pennathur S,
    3. Green PS,
    4. Gharib SA,
    5. Hoofnagle AN,
    6. Cheung MC,
    7. Byun J,
    8. Vuletic S,
    9. Kassim S,
    10. Singh P,
    11. Chea H,
    12. Knopp RH,
    13. Brunzell J,
    14. Geary R,
    15. Chait A,
    16. Zhao XQ,
    17. Elkon K,
    18. Marcovina S,
    19. Ridker P,
    20. Oram JF,
    21. Heinecke JW
    : Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117: 746–756, 2007pmid:17332893
    OpenUrlCrossRefPubMed
  26. ↵
    1. Riwanto M,
    2. Rohrer L,
    3. Roschitzki B,
    4. Besler C,
    5. Mocharla P,
    6. Mueller M,
    7. Perisa D,
    8. Heinrich K,
    9. Altwegg L,
    10. von Eckardstein A,
    11. Lüscher TF,
    12. Landmesser U
    : Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: Role of high-density lipoprotein-proteome remodeling. Circulation 127: 891–904, 2013pmid:23349247
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Tölle M,
    2. Huang T,
    3. Schuchardt M,
    4. Jankowski V,
    5. Prüfer N,
    6. Jankowski J,
    7. Tietge UJ,
    8. Zidek W,
    9. van der Giet M
    : High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 94: 154–162, 2012pmid:22328092
    OpenUrlCrossRefPubMed
  28. ↵
    1. Watanabe J,
    2. Charles-Schoeman C,
    3. Miao Y,
    4. Elashoff D,
    5. Lee YY,
    6. Katselis G,
    7. Lee TD,
    8. Reddy ST
    : Proteomic profiling following immunoaffinity capture of high-density lipoprotein: Association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 64: 1828–1837, 2012pmid:22231638
    OpenUrlCrossRefPubMed
  29. ↵
    1. Alwaili K,
    2. Bailey D,
    3. Awan Z,
    4. Bailey SD,
    5. Ruel I,
    6. Hafiane A,
    7. Krimbou L,
    8. Laboissiere S,
    9. Genest J
    : The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 1821: 405–415, 2012pmid:21840418
    OpenUrlCrossRefPubMed
  30. ↵
    1. Wanner C,
    2. Krane V,
    3. März W,
    4. Olschewski M,
    5. Asmus HG,
    6. Krämer W,
    7. Kühn KW,
    8. Kütemeyer H,
    9. Mann JF,
    10. Ruf G,
    11. Ritz E,
    12. Deutsche Diabetes-Dialyse-Studie (4D) Study Group
    : Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): Demographic and baseline characteristics. Kidney Blood Press Res 27: 259–266, 2004pmid:15316128
    OpenUrlCrossRefPubMed
    1. Wanner C,
    2. Krane V,
    3. März W,
    4. Olschewski M,
    5. Mann JF,
    6. Ruf G,
    7. Ritz E,
    8. German Diabetes and Dialysis Study Investigators
    : Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238–248, 2005pmid:16034009
    OpenUrlCrossRefPubMed
  31. ↵
    1. Wanner C,
    2. Krane V,
    3. Ruf G,
    4. März W,
    5. Ritz E,
    6. Die Deutsche Diabetes Dialyse Studie Investigators
    : Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Kidney Int Suppl 71: S222–S226, 1999pmid:10412782
    OpenUrlPubMed
  32. ↵
    1. März W,
    2. Genser B,
    3. Drechsler C,
    4. Krane V,
    5. Grammer TB,
    6. Ritz E,
    7. Stojakovic T,
    8. Scharnagl H,
    9. Winkler K,
    10. Holme I,
    11. Holdaas H,
    12. Wanner C,
    13. German Diabetes and Dialysis Study Investigators
    : Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 6: 1316–1325, 2011pmid:21493741
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Kwan BC,
    2. Kronenberg F,
    3. Beddhu S,
    4. Cheung AK
    : Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18: 1246–1261, 2007pmid:17360943
    OpenUrlFREE Full Text
    1. Moradi H,
    2. Vaziri ND,
    3. Kashyap ML,
    4. Said HM,
    5. Kalantar-Zadeh K
    : Role of HDL dysfunction in end-stage renal disease: A double-edged sword. J Ren Nutr 23: 203–206, 2013pmid:23611547
    OpenUrlCrossRefPubMed
  34. ↵
    1. Kilpatrick RD,
    2. McAllister CJ,
    3. Kovesdy CP,
    4. Derose SF,
    5. Kopple JD,
    6. Kalantar-Zadeh K
    : Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 18: 293–303, 2007pmid:17167113
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Chang YT,
    2. Wu JL,
    3. Hsu CC,
    4. Wang JD,
    5. Sung JM
    : Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: A nationwide follow-up study during 1998-2009. Diabetes Care 37: 277–285, 2014pmid:23920086
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Jardine MJ,
    2. Hata J,
    3. Woodward M,
    4. Perkovic V,
    5. Ninomiya T,
    6. Arima H,
    7. Zoungas S,
    8. Cass A,
    9. Patel A,
    10. Marre M,
    11. Mancia G,
    12. Mogensen CE,
    13. Poulter N,
    14. Chalmers J,
    15. ADVANCE Collaborative Group
    : Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis 60: 770–778, 2012pmid:22694950
    OpenUrlCrossRefPubMed
  37. ↵
    1. Shah AS,
    2. Tan L,
    3. Long JL,
    4. Davidson WS
    : Proteomic diversity of high density lipoproteins: Our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 54: 2575–2585, 2013pmid:23434634
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Whitehead AS,
    2. de Beer MC,
    3. Steel DM,
    4. Rits M,
    5. Lelias JM,
    6. Lane WS,
    7. de Beer FC
    : Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem 267: 3862–3867, 1992pmid:1740433
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Doyle IR,
    2. Bersten AD,
    3. Nicholas TE
    : Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure. Am J Respir Crit Care Med 156: 1217–1229, 1997pmid:9351625
    OpenUrlCrossRefPubMed
  40. ↵
    1. Nguyen AB,
    2. Rohatgi A,
    3. Garcia CK,
    4. Ayers CR,
    5. Das SR,
    6. Lakoski SG,
    7. Berry JD,
    8. Khera A,
    9. McGuire DK,
    10. de Lemos JA
    : Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: The Dallas Heart Study. Arterioscler Thromb Vasc Biol 31: 2136–2143, 2011pmid:21817103
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Rosenson RS,
    2. Brewer HB Jr..,
    3. Ansell B,
    4. Barter P,
    5. Chapman MJ,
    6. Heinecke JW,
    7. Kontush A,
    8. Tall AR,
    9. Webb NR
    : Translation of high-density lipoprotein function into clinical practice: Current prospects and future challenges. Circulation 128: 1256–1267, 2013pmid:24019446
    OpenUrlFREE Full Text
  42. ↵
    1. Mora S,
    2. Glynn RJ,
    3. Ridker PM
    : High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 128: 1189–1197, 2013pmid:24002795
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 10 (2)
Clinical Journal of the American Society of Nephrology
Vol. 10, Issue 2
February 06, 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Quantification of HDL Proteins, Cardiac Events, and Mortality in Patients with Type 2 Diabetes on Hemodialysis
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Quantification of HDL Proteins, Cardiac Events, and Mortality in Patients with Type 2 Diabetes on Hemodialysis
Chantal Kopecky, Bernd Genser, Christiane Drechsler, Vera Krane, Christopher C. Kaltenecker, Markus Hengstschläger, Winfried März, Christoph Wanner, Marcus D. Säemann, Thomas Weichhart
CJASN Feb 2015, 10 (2) 224-231; DOI: 10.2215/CJN.06560714

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Quantification of HDL Proteins, Cardiac Events, and Mortality in Patients with Type 2 Diabetes on Hemodialysis
Chantal Kopecky, Bernd Genser, Christiane Drechsler, Vera Krane, Christopher C. Kaltenecker, Markus Hengstschläger, Winfried März, Christoph Wanner, Marcus D. Säemann, Thomas Weichhart
CJASN Feb 2015, 10 (2) 224-231; DOI: 10.2215/CJN.06560714
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Association of Polypharmacy with Kidney Disease Progression in Adults with CKD
  • The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
  • Collectin11 and Complement Activation in IgA Nephropathy
Show more Original Articles

Epidemiology and Outcomes

  • Urine Kidney Injury Biomarkers and Risks of Cardiovascular Disease Events and All-Cause Death: The CRIC Study
  • Temporal and Demographic Trends in Glomerular Disease Epidemiology in the Southeastern United States, 1986–2015
  • Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD
Show more Epidemiology and Outcomes

Cited By...

  • Sensitive and reproducible determination of clinical HDL proteotypes
  • Modified lipoproteins in periodontitis: a link to cardiovascular disease?
  • Alteration of HDL Protein Composition with Hemodialysis Initiation
  • HDL functionality and cardiovascular outcome among nondialysis chronic kidney disease patients
  • HDL in CKD--The Devil Is in the Detail
  • HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients
  • Google Scholar

Similar Articles

Related Articles

  • PubMed
  • Google Scholar

Keywords

  • dialysis
  • cardiovascular disease
  • lipids

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire